ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2113

Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients

Mohamed Abdelsalam1, yasmeen Alabdallat2, Yousef Hussein3, Mona Sajed4, Maryam Taha5, Rawan morse6, Wessam Selima7 and Ahmed Zabady8, 1Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, 2Faculty of medicine - Hashemite university, Zarqa, Jordan, 3Faculty of medicine - Benha university, Benha, Egypt, 4Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt, 5Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt, 6Medical Research Group of Egypt, Bur sa'id, Egypt, 7Anaesethia & pain management department, Faculty of medicine, Ain Shams University, Cairo, Egypt, 8Faculty of science - Damanhour university, Cairo, Egypt

Meeting: ACR Convergence 2024

Keywords: Clinical Osteoporosis, clinical trial, osteoporosis, Randomized Trial, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Postmenopausal osteoporosis (PMOP) significantly contributes to global fracture rates annually, with its silent progression complicating early detection and intervention. Effective management strategies are crucial, including both non-pharmacological and pharmacological approaches. Despite many randomized clinical trials (RCTs) targeting PMOP, numerous trials remain unpublished or discontinued, hindering scientific progress and patient care. This study aims to analyze the prevalence, characteristics, and publication history of PMOP clinical studies and investigate reasons for their non-publication or discontinuation.

Methods: We thoroughly searched clinicaltrials.gov for PMOP trials up to December 31, 2021. We excluded studies completed within the last 24 months to allow for ongoing peer review. Using NCT identifiers, we identified published trials. Data on gender, age, study type, funding, intervention, enrollment, and location were extracted (Figure 1). Multiple logistic regression analyzed characteristics linked to unpublished or discontinued trials. 

Results: The search identified 414 trials focusing on PMOP. The main study type was interventional studies 362 (87.4%), with drug intervention being the majority 293 (73.6%). More than half of studies recruited over one hundred patients 240 (59.6%), with industrial fund being the primary source 254 (61.4%). 345,435 patients participated in all trials with completion of 389 (93.96%). However, twenty-five studies were discontinued with an exposure of 17,582 patients (Table 1). Moreover, more than half of all trials (54.3%) remained unpublished, exposing 215,833 patients to unnecessary risk. Of the discontinued studies, 16 (64%) were terminated, and the remaining were withdrawn. The logistic regression analysis revealed that studies with an enrollment of less than one hundred participants (OR =0.0589, 95% CI [-4.932, -0.733], p = 0.008) were associated with significantly lower odds of completion. Meanwhile, studies funded by non-industry sources had significantly lower odds of publication (OR = 0.487, 95% CI [-1.346, -0.0937], p = 0.024). Notably, the United States had the highest number of discontinued studies (61.54%) despite only conducting (38.2%) of PMOP total studies (Figure 2).

Conclusion: This is the foremost crosssectional analysis of PMOP clinical studies. The analysis revealed that two-thirds of the patients were enrolled in either discontinued or non-published PMOP clinical studies and that the United States lead the world in the number of discontinued PMOP studies. The high incidence of unpublished and discontinued studies results in exposing participants to potentially ineffective or harmful interventions without generating useful findings. To enhance trial outcomes and improve patient care in PMOP management, future clinical studies must address the barriers of low enrollment and insufficient funding. Addressing these issues is essential for advancing scientific knowledge and optimizing the effectiveness of PMOP interventions.

Supporting image 1

Figure (1) PRISMA Flow Chart Illustrating Search Strategy and Selection of Included Studies

Supporting image 2

(Figure 2) Global Distribution of completed and discontinued clinicals studies by Country.

Supporting image 3

(Table 1) Characteristics and outcomes of postmenopausal osteoporosis (PMOP) clinical trials by completed, discontinued, published and nonpublished status.


Disclosures: M. Abdelsalam: None; y. Alabdallat: None; Y. Hussein: None; M. Sajed: None; M. Taha: None; R. morse: None; W. Selima: None; A. Zabady: None.

To cite this abstract in AMA style:

Abdelsalam M, Alabdallat y, Hussein Y, Sajed M, Taha M, morse R, Selima W, Zabady A. Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/discontinuation-and-non-publication-of-postmenopausal-osteoporosis-clinical-studies-a-cross-sectional-analysis-of-345435-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/discontinuation-and-non-publication-of-postmenopausal-osteoporosis-clinical-studies-a-cross-sectional-analysis-of-345435-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology